Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ovid Therapeutics (OVID) Accumulated Expenses (2020 - 2025)

Ovid Therapeutics' Accumulated Expenses history spans 6 years, with the latest figure at $4.9 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 18.27% year-over-year to $4.9 million; the TTM value through Dec 2025 reached $4.9 million, down 18.27%, while the annual FY2025 figure was $4.9 million, 18.27% down from the prior year.
  • Accumulated Expenses reached $4.9 million in Q4 2025 per OVID's latest filing, up from $3.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $13.2 million in Q1 2021 to a low of $2.9 million in Q2 2025.
  • Average Accumulated Expenses over 5 years is $6.1 million, with a median of $5.8 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 1198.88% in 2021, then tumbled 64.58% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $7.7 million in 2021, then tumbled by 41.28% to $4.5 million in 2022, then soared by 44.83% to $6.5 million in 2023, then fell by 8.12% to $6.0 million in 2024, then decreased by 18.27% to $4.9 million in 2025.
  • Per Business Quant, the three most recent readings for OVID's Accumulated Expenses are $4.9 million (Q4 2025), $3.0 million (Q3 2025), and $2.9 million (Q2 2025).